Table 2 Main characteristics of PNSs experienced by patients selected for analysis after central review
Results | Patients with pre-existing PNS (cohort 1), n = 16 | Patients with newly diagnosed PNS (cohort 2), n = 16 | Total patients n = 32 |
|---|---|---|---|
Time from diagnosis of cancer to diagnosis of the PNS, median (range), months | 0.3 (−62.8;406.2)a | 18.6 (3.9;281.5) | 11.9 (−62.8;406.2) |
Neurologic PNS, n patients (%) | 4 (25) | 7 (44) | 11 (34) |
- Encephalitis | 1 | 5 | 6 |
- Neuropathy | 2 | 1 | 3 |
- Lambert-Eaton syndrome | 1 | 1 | 2 |
Rheumatologic PNS, n patients (%) | 3 (19) | 6 (38) | 9 (28) |
- Hypertrophic osteoarthropathy | 2 | 4 | 6 |
- RS3PE | 0 | 2 | 2 |
- Rhizomelic pseudopolyarthritis | 1 | 0 | 1 |
Connective tissue PNS, n patients (%) | 6 (37) | 2 (12) | 8 (25) |
- Dermatomyositis | 4 | 1 | 5 |
- Systemic sclerosis | 1 | 1 | 2 |
- Myositis (anti-PL7 antisynthetase syndrome) | 1 | 0 | 1 |
Other PNSs, n patients (%) | 3 (19) | 1 (6) | 4 (13) |
- Membranous nephropathy | 1 | 0 | 1 |
- IgA vasculitis or Henoch-Schönlein purpura | 1 | 0 | 1 |
- Other, thrombotic microangiopathy | 1 | 0 | 1 |
- Other, Cushing’s disease | 0 | 1 | 1 |
Highest CTCAE grade for PNS severity, n of patients (%) | |||
- Grade 1–2 | 5 (31) | 5 (31) | 10 (31) |
- Grade 3–4 | 11 (69) | 7 (43) | 18 (56) |
- Grade 5 | 0 | 4 (25) | 4 (13) |
CTCAE grade for PNS severity at last follow-up, n of patients (%) | |||
- Grade 0–1 | 7 (44) | 5 (31) | 12 (38) |
- Grade ≥ 2 | 9 (56) | 11 (69) | 20 (62) |
Causes of death, n of patients (%) | 3 (19) | 6 (38) | 9 (28) |
- PNS | 0 | 4 | 4 (13) |
- tumor progression | 2 | 2 | 4 (13) |
- comorbidity | 1 | 0 | 1 (3) |